ESC 365 - Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

ESC Professional Premium Access

Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in preclinical individuals with an HCM sarcomeric gene mutation

Session: Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Topic: Hypertrophic Cardiomyopathy

Speaker: Mr B. Van Driel (Amsterdam, NL)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Mr Beau Van Driel

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

0 follower

4 more presentations in this session

State-of-the-art lecture on novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speaker: Doctor C. Ho (Boston, US)

Long-term safety and efficacy of mavacamten in obstructive hypertrophic cardiomyopathy: up to 3.5-year follow-up results of the EXPLORER cohort of MAVA-Long-Term Extension study

Speaker: Doctor P. Garcia-Pavia (Majadahonda, ES)

Clinical application of biomarkers in obstructive hypertrophic cardiomyopathy: insights from SEQUOIA-HCM

Speaker: Doctor C. Coats (Glasgow, GB)

Aficamten in patients with obstructive hypertrophic cardiomyopathy: an integrated safety analysis

Speaker: Doctor A. Masri (Portland, US)

Access the full session

Novel therapies for hypertrophic cardiomyopathy: recent developments and future prospects

Speakers: Mr B. Van Driel, Doctor C. Ho, Doctor P. Garcia-Pavia, Doctor C. Coats, Doctor A. Masri

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources